Avertissement sur les risques : Les produits à effet de levier présentent un niveau de risque élevé et peuvent entraîner la perte de tout votre capital. Assurez-vous de bien comprendre les risques avant d’investir.
Avertissement sur les risques : Les produits à effet de levier présentent un niveau de risque élevé et peuvent entraîner la perte de tout votre capital. Assurez-vous de bien comprendre les risques avant d’investir.

Current region:

  • Français
    ACTIVE
Other languages:
  • Español – Spanish
  • Português – Portuguese
  • English – International
  • Tiếng Việt – Vietnamese
  • Français – French
  • ไทย – Thai
  • العربية – Arabic
Avertissement sur les risques : Les produits à effet de levier présentent un niveau de risque élevé et peuvent entraîner la perte de tout votre capital. Assurez-vous de bien comprendre les risques avant d’investir.

AMD, Palantir, and Super Micro in Focus

U.S. stocks are in focus today as investors track key corporate updates across technology, healthcare, and energy. Palantir gained after raising its full-year forecast, while Hims came under pressure following its break with Novo Nordisk and weaker sales. BP also moved higher, supported by improved margins and fresh cost-cutting measures.

Key Points:

  • Palantir rises 6% after lifting its full-year forecast.
  • Hims dropped 10% following a break with Novo Nordisk and disappointing sales.
  • BP gains 2.5% on improved margins and announced cost cuts.

Palantir (PLTR): Momentum from Upward Guidance

Palantir gained 6% in premarket trading after reporting quarterly earnings that surpassed expectations and raising its full-year outlook. The company continues to benefit from growing demand for its AI-driven software offerings.

Hims & Hers (HIMS), Novo Nordisk (NVO): Declines on Partnership Fallout and Weak Results

Shares of Hims fell over 10% after missing revenue estimates. The stock was further pressured by tensions with Novo Nordisk, sparked by Hims’ offering of generic weight-loss medications via its platform.

Vertex Pharmaceuticals (VRTX): Setback Following Clinical Trial Decision

Vertex declined 14% in after-hours trading after announcing it will halt development of its experimental pain treatment, despite promising early-stage data. The decision underscores the company’s reliance on its late-stage pipeline.

DuPont de Nemours (DD): Strong Sales and Upbeat Outlook

DuPont rose 7% in premarket trading after exceeding sales projections and issuing guidance above analyst expectations. Its specialty materials division showed resilience amid uneven end-market demand.

BP (BP), Diageo (DEO): Gains Despite External Pressures

BP advanced 2.5% after reporting stronger profitability metrics and introducing additional cost-saving initiatives. Diageo added 2% despite forecasting a $200 million annual tariff impact.

Advanced Micro Devices (AMD), Super Micro (SMCI), Snap (SNAP): Key Earnings Ahead

Investors are watching earnings reports from AMD, Super Micro Computer, and Snap, all due Tuesday. These results will offer insight into demand trends for high-performance chips, server infrastructure, and social media platforms amid a still-recovering tech landscape.

Related posts

Outlook EN

Weekly Market Outlook | 17–21 August

Markets have a new question to price this week: how divided is the Fed, and what does that mean for

Oil Rises as Iran Tensions

Oil Rises as Iran Tensions Persist

Oil prices remained broadly stable on Friday, August 14, as geopolitical risks in the Middle East continued to support crude,

Technical Analysis-EN

XAUUSD Tests $4,450 as Fed Eases

Gold prices remained broadly steady on Thursday, August 13, after rallying to a fresh two-month high in the previous session.